

Poster presentations

Tuesday, 18 April 2023

14:00-15:30 Poster Session I (In person)

Venue: Second Floor, M02 Exhibition Area

Poster ID	Name	Organizations	Title of Paper
5	Jose Luis CRUDO	Argentina	Specific Activity Retrospective Analysis of Lu-177(c.a.) Locally Produced and Comparative Requirements for 177Lu-DOTA-peptides Preparation
6	Ralph SANTOS-OLIVEIRA	Brazil	Alpha-Beta-Targeted Therapy
7	Ala' KHWAJ	Jordan	Radiopharmaceutical Production in Hashemite Kingdom of Jordan
10	Hun Yee TAN	Malaysia	In-vivo Therapeutic Efficacy of Samarium-153 Oxide Loaded Polystyrene Microspheres in Liver Tumour-Bearing Rats
11	Inaam Ayoub Said KHALIL	Jordan	Radiopharmaceuticals and their Applications: Role of Pharmacists as Community Educators
12	Ramon HERNANDEZ ALVAREZ	Cuba	Regulatory Harmonization Between Different Authorities Involved in the Radiopharmaceutical Production: Essential Action and a Challenge to Face.
13	Seble Shambel ENYEW	Ethiopia	Regulatory Status for Radiopharmaceuticals in Ethiopia
15	Tamer Mostafa Mohamed Hafez SAKR	Egypt	Preparation and Biological Evaluation of 68Ga-WSSF-DOTA-Bombesine Nanoparticle
17	Mohamed Ahmed Elwany ELGIZAWY	Egypt	Computational Study and Preclinical Evaluation of a Novel Radiosynthesized 47Sc-Dipeptide Derivative as a Promising Cancer Theranostic Agent
19	Maria Emilia TEJERÍA	Uruguay	Development and initial evaluation of two 99mTc complexes derived from a fibroblast activating protein (FAP) inhibitor
20	Josephine NAMUTEBI	Uganda	Africa's Next Radiopharmacists- Ways Forward for Education and Career Opportunities.
21	Hesham Abdelaal Abdelmoaty SHAMSELDIN	Egypt	Efficient Separation of Carrier-free 47Sc Adequate for Radiotheranostic Applications Through natTi(n,p) Reaction
25	Adli Abdalla Selim ABDELMAKSOUND	Egypt	Synthesis of [131I]-Quercetin/Ascorbic Acid Coated Selenium Nanoparticles for Inflammation Theranosis
26	Hesham ELKHATIB	Egypt	Modeling and Assessment of Radioactive Iodine Dispersion Inside Egyptian Radioisotope Production Facility
28	Mohamed SWIDAN	Egypt	Development and In-vivo Evaluation of Chelator Free 123/131I-silver Nano-probe For Theranostic Applications
29	Maria Elisa CHUERY M. ROSTELATO	Brazil	Nationalization of Brachytherapy Radioactive Sources in Brazil and the Importance of IAEA Cooperation
30	Maria Elisa CHUERY M. ROSTELATO	Brazil	Synthesis, Activation and Application Testing of Gold Nanoparticles for Nanobrachytherapy
31	Maria Elisa CHUERY M. ROSTELATO	Brazil	Challenges in Iodine-125 Sources Production for Cancer Treatment
35	Robert SSEKAJJUGO	Uganda	Collaborative and Reliance Procedures in the Regulation of Radiopharmaceuticals in the Regional Economic Blocks of Low- and Middle-Income Countries – Prospects for the East African Community
36	Archana MUKHERJEE	India	Novel Ubiquitin Conjugate for Bacterial Infection Imaging
40	Ahmed Badr Ibrahim ABDALLAH	Egypt	Route of Administration Studies for Brain Targeting by Optimized 99mTc-olanzapine

Poster ID	Name		Organizations	Title of Paper
41	Yen	NG	Malaysia	Synthesis and Characterization of High Purity Iu-177-dotanoc: In-house Production Experience and the Way Forward
42	Shishu	SUMAN	India	A Nanoliposomal Formulation for Dosimetry and Combination Radionuclide Therapy of Breast Cancer
44	Priscilla	BRUNELLI PUJATTI	Brazil	Clinical Pharmaceutical Screening as a Tool to Improve Radioiodine Therapy Safety: Descriptive Study of Two Years' Experience
48	Priscilla	BRUNELLI PUJATTI	Brazil	Hospital Radiopharmacy Training Program for Pharmacists: Experience in a Reference Hospital in Brazil
53	Ana	REY RIOS	Uruguay	Virtuality as a Tool to Expand Educational Offer in Radiopharmacy in Latin-America
55	Marlina	MARLINA	Indonesia	Development of 99Mo/99mTc Generator Based on Low Specific Activity of Molybdenum-99 (99Mo) in Indonesia
64	Michael	HASCHKE	Germany	Sustainable REE Production by Th-232 Processing into Ac-225 for radiopharmaceutical cancer treatment
67	Clara Leticia	SANTOS CUEVAS	Mexico	Imaging of the Tumor Microenvironment via SPECT/CT with [99mTc]Tc-iFAP: Kinetics, Radiation Dosimetry and Imaging in Patients
74	Aleksandar	VUKADINOVIC	Serbia	Preparation and Preclinical Evaluation of 90Y- and 177Lu-labeled Nanoparticles for Solid Tumor Therapy
75	Jorge	ROMERO	Chile	Preliminary Studies for the Implementation of a Synthesis Method and Quality Control of [18F]PSMA-1007: a New Radiotracer for Prostate Cancer in the Chilean Public Health System
76	Oscar	POZZI	Argentina	Development of New Type Target for Production of 177Lu Of High S.A. in Reactors of Low-Medium Neutron Flux
79	Isti	DARUWATI	Indonesia	Radiolabeling of Novel Alpha Mangostin Eerivate, Physico-chemical Properties and Cellular Uptake to T-47D human Cell Line as A Theranostics Radiopharmaceutical Candidate for Breast Cancer
81	Ajaghen	SEENEEVASSEN	Mauritius	"From a Participant's Perspective: IAEA Sponsored MSc Radiopharmacy – Experience, Outcomes and Recommendations"
82	Blanca	OCAMPO GARCIA	Mexico	Synthesis and Preclinical Evaluation of 177Lu-NP(RGF)-CXCR4L as a New Nanoradiopharmaceutical for Colorectal Cancer Treatment
83	Fany Pricile	EKOUME	Cameroon	Status, Opportunities and Future Direction of Radiopharmacy Practice in Africa
91	Putthiporn	CHAROENPHUN	Thailand	Moving Forward of Radiopharmacy Education in Thailand
94	Abdul Hamid	AL RAYYES	Syrian Arab Republic	Cyclotron Production and Quality Control of 68Ga Using High Power Solid Target for Theranostic Applications
97	Kanchan	KUSHWAHA	India	Production and Radiochemical Separation of 89Zr via 89Y(p,n)89Zr Route Using an Indigenously Developed Solid Target Irradiation Assembly
99	Kanchan	KUSHWAHA	India	Theoretical Estimation of Radiation Safety Parameters in 111In Production via 111Cd(p,n)111In route Using Indigenously Developed Solid Target Assembly
101	Muhammad	SHAHID	Pakistan	Radionuclidic Impurities in Medical Radioisotopes and Regulatory Concerns in Patient Dose
102	Kendall	BARRETT	United States of America	Radiochemical Isolation of Cyclotron Produced Positron-emitting 51Mn Using N,N,N',N'-tetra-n-Octyldiglycolamide (DGA) Resin
103	Thaer	ASSAAD	Syrian Arab Republic	In House Preparation and Biodistribution of 90YCl, 90Y-DOTATATE, 90Y-FHMA and 90Y-EDTMP for Therapeutic Application

Poster ID	Name		Organizations	Title of Paper
104	Ana Clarisa	LOPEZ BULARTE	Argentina	Project Concept Paper (PCP) presented in IAEA-KOICA-KAERI Joint Training Programme: CNEA Coordinated Project for Clinical Translation of Theragnostic Radiopharmaceuticals in Argentina
105	Aaru	SANO	Japan	Ac-225 Production Using the Experimental Fast Reactor Joyo
106	Chiba	YUSUKE	Japan	Challenge for Mo-99/Tc-99m Production by JRR-3
107	Hassan	YOUSEFNIA	Iran, Islamic Republic of	Development of [89Zr]Zr-DFO-Trastuzumab for immune PET Imaging of HER2+ Tumors
108	Hassan	YOUSEFNIA	Iran, Islamic Republic of	Development of [89Zr]Zr-PSMA-617 for Prostate Cancer PET Imaging
111	Amreeta	MANGATHA	Mauritius	Establishing Good Radiopharmacy Practice in Mauritius: A case study for Africa
113	Aleksander	BILEWICZ	Poland	Platinum Nanoparticles Labeled with Iodine-125 for Combined „Chemo-Auger Electron” Therapy of Hepatocellular Carcinoma
114	Tossaporn	SIRIPRAPA	Thailand	Development and Validation Method of Gas Chromatography for Quality Control of Organic Solvents in [F-18] Florbetapir
115	Nasrin	ABBASI GHARIBKANDI	Poland	Bioconjugates of 103Pd/103mRh in-vivo Generator for Targeted Auger Electron Therapy
116	Ihab	SHOKAIR	Poland	Organic Boron-Derivatives for Radiohalogenation of Biomolecules
120	Boon-Uma	JOWANARIDHI	Thailand	Development of PSMA Kit as Ga-68 Radiopharmaceutical for Diagnosis of Prostate Cancer
122	Arni	ARIES	Indonesia	Estimated Human Dose of Technetium-99m Derived from Low Specific Activity 99Mo/99mTc Generator: Preliminary Study
123	Bibigul	KALIYASKAROVA	Kazakhstan	Quality Control of the 18F-FDG Radiopharmaceutical at the Center for Nuclear Medicine and Oncology in Semey.
128	Karn	WIMOLWATTANA SARN	Thailand	Method Development and Validation for the Determination of Residual Solvents in [F-18] FPSMA-1007 Radiopharmaceutical by Using Gas Chromatography.
129	Geeva Prasanth	ANNAMALAISAMY	Poland	Preparation and Characterization of Palladium-103/109 Bisphosphonate - 2,2' Bipyridyl Complexes for the Treatment of Bone Cancer Metastasis – Preliminary Studies.
133	Fawzy	MARZOOK	Egypt	Synthesis and Radioiodination of (z)-3-ethoxy-methylene) 2,3 dihydro-5,7-dimethylthiopyrano [2,3-b] pyridine -4-one as a Potential Antitumor
136	Katerina	ONDRAK FIALOVA	Czech Republic	Cerium(IV) Oxide as a Matrix for a Radionuclide Generator
137	Samaneh	ZOLGHADRI	Iran, Islamic Republic of	Development of 64Cu-DOTATATE for PET Imaging of Somatostatin Receptor Positive Neuroendocrine Tumors
139	Teguh	WIBAWA	Indonesia	Simple Preparation of Novel [99mTc] Tc-Pramipexole Radiopharmaceutical as A Potential Agent for Brain Imaging
142	Przemyslaw Andrezej	KOZMINSKI	Poland	Synthesis of New Azobenzene Derivatives Radiolabelled with Gallium-68 as new Imaging Agents for the Diagnosis of Alzheimer's Disease
143	Ewa	GNIAZDOWSKA	Poland	Radiolabeled Inhibitors of VEGF-A165/NRP-1 Complex for Pathological Angiogenesis Imaging
144	Behrouz	ALIREZAPOUR	Iran, Islamic Republic of	Cyclotron Production of 68Ga Via the 68Zn(p,n)68Ga Reaction From Solid Target for Preparation of Radiotracers

Poster ID	Name		Organizations	Title of Paper
146	Rabeya	AKHTER	Bangladesh	Production and Quality Control of ^{99m} Tc-Radiopharmaceuticals
147	Momtaz	WAHEED	Bangladesh	Advancement of Radioisotope Production and Nuclear Medicine: Perspective Bangladesh
148	Jorge	ROMERO	Chile	Chemical Purity Evaluation Method of the Hynic-psma Lyophilized Kit by High Performance Liquid Chromatography
150	Kinga	ZELECHOWSKA-MATYSIAK	Poland	Radioactive Gold Nanoparticles Modified with Doxorubicin and Trastuzumab (DOX-PEG-198AuNPs-PEG-Tmab) for Targeted Radionuclide Therapy of HER2-Positive Cancers
152	Romain	COULON	France	Traceability for Nuclear Medicine: The Status of Primary Radioactivity Standards
173	Maia	ZENI RODRIGUEZ CARVALHO	Uruguay	[¹¹ C]KEN a Potential GSK-3 β Imaging Agent in the Alzheimer's Disease.
178	Marina	BICALHO SILVEIRA	Brazil	Development of 3d-Printed Mice Phantom for Micropet System Calibration
181	Emilia Teresa	MAJKA	Poland	Synthesis of Gold Nanoparticles Labeled with Auger Electron Emitters: ¹⁹⁷ Hg/ ^{197m} Hg as Potential Therapeutic Radiopharmaceuticals
194	Matyas	FODOR	Hungary	Synthera+ Platform Application of ⁶⁸ Ga, Produced From ⁶⁸ Zn Using HCl Medium
195	Arshiya	ANEES AHMED	Poland	Production of Sc Radioisotopes by Proton-induced Reaction on CaO Target
199	Anna	KRZYCZMONIK	Poland	Radioiodination of Novel Prosthetic Groups for Disulfide Rebridging
238	Yizheng	WANG	France	Production of the Theranostic Radioisotope ¹⁵⁵ Tb in Biomedical Cyclotrons Using Enriched ¹⁵⁵ Gd Targets

Tuesday, 18 April 2023

14:00-15:30 Virtual E-poster I

Venue: Second Floor, M02 Exhibition Area E-Poster Stations

Poster ID	Name	Organizations	Title of Paper
14	Shahzad	FEIZIZENJANAB Iran, Islamic Republic of	A New Production Route of Zirconium-89 Radiopharmaceuticals for PET Imaging with Cyclone-30 Cyclotron
22	Alfitri	MELIANA Indonesia	Qualification and Certification Process for Radioisotopes and Radiopharmaceuticals Operators and Supervisors in Indonesia
37	Akanksha	JAIN India	68Ga-Labeling of HBED-CC Conjugated Cell Penetrating Peptide Coupled with Tyrosine Kinase Inhibitor, Erlotinib
39	Irvan Dwi	JUNianto Indonesia	Developing Questions Bank for Radioisotopes Radiopharmaceuticals Personnel Certification Based on the Result of Validity Analysis
49	Erika	AZORIN VEGA Mexico	Radiobiological and Dosimetric Characterization of Molecular Radiopharmaceuticals at the Cellular Level
51	Barbara Beatriz	DIAS RODRIGUES Brazil	68Ge/68Ga Generator in Nuclear Medicine and Licensing Aspects: Brazil's Situation
66	Sankha	CHATTOPADHYAY India	Separation of Ge-68 From Ga-Ni Alloy Target for 68Ge/68Ga Generator Production
68	Mohammad Reza	ABOUDZADEH ROVAIS Iran, Islamic Republic of	Feasibility Study on Production of 195mPt in Tehran Research Reactor
69	Sara	VOSOUGHI Iran, Islamic Republic of	Human Dosimetry Calculation of 188Re-Hynic-Bombesin
70	Mohammad Reza	ABOUDZADEH ROVAIS Iran, Islamic Republic of	Scandium-47 Production by Cyclotron Irradiation of Titanium Targets
78	Myrna	LUNA GUTIÉRREZ Mexico	Development of a new radiopharmaceutical of 99mTc-HYNIC-iFAP for the detection of different types of cancer of epithelial origin by SPECT images.
77	Yulaida Maya	SARI Indonesia	Gap Analysis Review of LSP BATAN's Radioisotopes and Radiopharmaceuticals Personnel Certification Management System Following the Organizational Merger with BRIN
85	Nafise	SALEK Iran, Islamic Republic of	Production of Terbium-161 as An Auger Emitter in Tehran Research Reactor
86	Avik	CHAKRABORTY India	Diagnostic Multidose Preparation of Ready-to-Use [64Cu] Cu-ATSM for Hypoxia Targeting Using Copper-64 Produced at GE Pettrace 860
87	Avik	CHAKRABORTY India	[68Ga] Ga-FAPI-4 and [18F]FDG in the Detection Non-Iodine Concentrating Thyroid Carcinoma
88	Avik	CHAKRABORTY India	Multidoses Formulation of [68Ga] Ga-WL12 and Its Preclinical Evaluation for Clinical Translation in Patients with Metastatic Breast and Cervical Cancer
90	Avik	CHAKRABORTY India	Gallium-68 Radiolabeled Bioactive Napthoquinoid Derivatives and Its Pre-Clinical Evaluation: PIN1 Potential Diagnostic Agents for Targeting PIN1 Positive Cancers
100	Zahra Khanum	KOUSRI Pakistan	"Regulatory Practices to Ensure Safe and Secure Production and Use of Radiopharmaceuticals in Pakistan"
117	Muhammad Hishar	HASSAN Malaysia	Optimal Radiolabeling Conditions for [18F] Aif-NOTA-Moiety
119	Luckson	GORONDONDO Zimbabwe	Regulatory Approach to the Use of Radiopharmaceuticals in Developing Countries
124	Raviteja	NANABALA India	Education and Training of Radiochemists in a GMP Certified Cyclotron Facility

Poster ID	Name		Organizations	Title of Paper
125	Raviteja	NANABALA	India	Setting Up a Clean Room Facility for GMP Based Production of Freeze-Dried Kits for Formulation of ^{99m} Tc and ⁶⁸ Ga Radiopharmaceuticals
127	Raviteja	NANABALA	India	[¹⁸ F] FDG Production: A Retrospective Analysis of 2300 Batches Using Different Synthesis Modules
130	German	RABI	Argentina	Regulatory Control of Ventilation Systems of Radiopharmaceuticals Production Facilities with Cyclotron
138	Tamanna	LAKHANPAL	India	Radiolabelled Plerixafor as a Theranostic Molecule for Targeting CXCR4 Receptor Over-Expression: Radiolabelling and in-Vitro Bioevaluation and Preclinical Biodistribution Study
141	Youssef	BOUDRAA	Morocco	Validation of Analytical Methods: Determination of Sodium Thiosulfate in Sodium ¹³¹ I Iodide Solutions by High Performance Liquid Chromatography
151	Daniela	CAMPOROTON DI	Argentina	Current Situation and Perspectives of the Radioisotopes Production for Nuclear Medicine Purposes in Ezeiza Atomic Centre
156	Titis	HUMANI	Indonesia	Development of a Simple, Robust, and High-Yielding Manual Production of [¹⁷⁷ Lu]Lu-PSMA I&T Using Carrier-Added Lutetium-177 in Indonesia
164	Jianguo	LI	China	Current Status of Non-Clinical Research on Radiopharmaceuticals in China
169	Mansur	TOKTOSINOV	Russian Federation	Registered Radiopharmaceuticals, Trends in Clinical Trials, the Role of Rosatom State Corporation
172	Sahar	NOSRATI SHANJANI	Poland	Radioiodinated Anti-HER2 Monoclonal Antibodies as Potential Therapeutic Radiopharmaceuticals
176	Derar	OMARI	Jordan	Radiopharmaceutical Education and Regulations in Jordan

Thursday, 20 April 2023

14:00-15:30 Poster Session II (In person)

Venue: Second Floor, M02 Exhibition Area

Poster ID	Name	Organizations	Title of Paper	
157	Jan Rijn	ZEEVAART	South Africa	64Cu/*Pd-Glucab: An in Vivo Albumin-Binding Theranostic Radiopharmaceutical for Dual Active and Passive Targeting of Breast Cancer
2	Alireza	KHORRAMI MOGHADDAM	Iran, Islamic Republic of	Development of [153] Sm-DOTA-Bevacizumab for radio targeted therapy in rat model (SW480 cell line)
3	Alireza	KHORRAMI MOGHADDAM	Iran, Islamic Republic of	Critical Organ Dose Estimation from Tc-99m-MIBI in Nuclear medicine cardiology based on distribution data in rats
153	Javier Gabriel	GIGLIO BAROSSO	Uruguay	Comparison of Three Different Alternatives for Labelling PSMA under GMP Conditions
154	Javier Gabriel	GIGLIO BAROSSO	Uruguay	Automated Synthesis of [18F]Favipiravir on a Synthra RNplus Research Platform
161	Jie	GAO	China	The Third Generation of Radioembolization Microspheres ——90Y Carbon Microspheres
165	Tesnim	DALLEGI	Tunisia	Synthesis and Biological Evaluation of 1-[2-(Cyclopentadienyltricarbonyltechnetium-99m)- N-Vanillylferrocenecarboxamide for Tumor Imaging
166	Laura	DE NARDO	Italy	47Sc Production: Comparison of the Natv(P,X) and 48Ti(P,X) Routes From the Dosimetric Point of View
167	Laura	DE NARDO	Italy	Cellular and Multicellular Dosimetry of Two Copper Radioisotopes: 67Cu and 64Cu
170	Analia	SOLDATI	Argentina	Women's Role in Radiopharmaceuticals Development and Production in Argentine
177	Mouldi	SAIDI	Tunisia	Synthesis and Evaluation of 99mtc-Lactoferrin for Detection of Staphylococcus Aureus Infections
179	Oleg	MANSUROV	Russian Federation	The Status and Prospects of Radiopharmaceutical Industry in Russia
186	Bhakti	SHETYE	India	Optimization of in-House Formulation of 177Lu-CHX-a''-DTPA-Trastuzumab for Diagnostic and Therapeutic Doses: An Institutional Review
187	Maria Teresa	BORRAS	Philippines	Acquiring GMP Status for Tc-99m Facility in the Philippines: Opportunities, Challenges and Lessons Learned
188	Laura	MELENDEZ ALAFORT	Italy	Assessment of Cell Damage Produced By 161Tb-/177Lu-Somatostatin Analog Radiopharmaceuticals
189	Laura	MELENDEZ ALAFORT	Italy	Preclinical Dosimetric Studies of 177Lu-Scfvd2b, 177Lu-PSMA-617 and 177Lu-Ipsma
190	Shaima	MOHAMED EP ABDALLAH	Tunisia	A Comprehensive Platform for Management the Production and Distribution of Radiopharmaceuticals
191	Repaka	KRISHNA MOHAN	India	Targeting Pancreatic Ductal Adenocarcinomas (PDAC) with Neuroendocrine Differentiation (NED) Subgroup of Tumours with Combination of 177Lutetium-DOTATATE and Dihydroxy Stilbene(DHS) Combination: Mechanistic Insights
192	Mario	MALINCONICO	Italy	Development of Solid Target Technologies for 225Ac Production with Proton Bombardment
193	Aicha Nour	LAOUAMERIA	Hungary	Radioisotope Separation of Platinum Group Elements for Potential Applications in Targeted Cancer Therapy
196	Hanadi	NAHAS	France	Evaluation of human hepatoma cells targeting of biocompatible and peptide-functionalised polymer nanoparticles encapsulating an imaging agent
200	Arifudin	ACHMAD	Indonesia	LAT1 Inhibitory Potency of ADFB-Based Cancer Theranostic Radiopharmaceutical Designs: A Molecular Docking Simulation

Poster ID	Name		Organizations	Title of Paper
211	Mariella	TERAN GRETTTER	Uruguay	Evaluation of Two Defensins Short Analogues as Potential Radiotracers for Detection of Infection Foci
220	Kaisar	TURAPBAY	Kazakhstan	NROC: Opportunities and Perspectives of Radiopharmaceuticals
216	Antonio Manuel	ROCHA PAULO	Portugal	Dual-Targeted ¹¹¹ In-Radiocomplexes for Auger Therapy of Prostate Cancer
217	Maria De Lurdes	BARRELA PATRICIO GANO	Portugal	Gold Nanoparticles for Image-Guided Delivery of Pt(IV) Prodrugs To Gastrin-Releasing Peptide Receptor Positive Cancers
226	Muhammed Anees	KUNNEKKADAN	India	Occupational Radiation Dose Management in a Medical Cyclotron Facility
224	Wilson	PAREJO CALVO	Brazil	Regulatory Requirements and Economic Feasibility for Developing a Mobile SPECT/CT Unit with Radiopharmacy Facilities
227	Muhammed Anees	KUNNEKKADAN	India	Radioactive Waste Management in Medical Cyclotron Facility
228	Charles	DOLL	United States of America	Overview of STAX Infrastructure Development and Current Detector Installations
229	Wilson	PAREJO CALVO	Brazil	Production and Application of ¹⁷⁷ Lu-PSMA and ²²⁵ Ac-PSMA in the Sustainable Innovation Model through Balanced Scorecard(BSC)
230	Célian Rene Marie	MICHEL	France	Occupational Radiation Protection of Undertakers and Crematorium Staff in Case of a Patient Death Shortly After Radionuclide Therapy
231	Bryce	NELSON	Canada	Experiences From Radiometal Production and Purification on A TR-24 Cyclotron at Edmonton's Medical Isotope and Cyclotron Facility
232	Dina	ABODEYAK	Jordan	Development and Validation of Manual Radiochemical Purity Test for Ga ⁶⁸ - Labelled Radiopharmaceuticals
236	Luna	BARUA	India	Direct Production of Ga-68 in 30 MeV DAE Medical Cyclotron and Subsequent Synthesis of ⁶⁸ Ga-PSMA-11 Radiopharmaceutical Using Indigenously Developed Semi-Automated Module
239	Vera	ARTIKO	Serbia	Radiolabeling of Ciprofloxacin in The Detection of Orthopedic Infections
240	Inês	MARQUES	Portugal	Radiobiological Effects of Radium-223 in 3D Cell Cultures of Metastatic Prostate Cancer
243	Sarah	MOSIMA	South Africa	Occupational Dosimetry of Staff in Clinical Routine Practice with [¹⁸ F]FDG in a New PET/CT Centre
244	Thomas	SOUNALET	France	Production of Pb-203 from target manufacturing to chemical separation Pb/Tl
247	Ben Hamou	KADDOUR	Morocco	Quantitative Formulation of Non-Carrier Added Sodium Iodide (Na, ¹³¹ I) Aqueous Solutions with Sodium Thiosulfate Reducing Agent: Theoretical Determination of Initial Concentration and Modeling of The Radio-Chemical Decomposition Kinetics
248	Samira	MARQUES DE CARVALHO	Brazil	New Regulatory Framework for Radioisotopes Production and Radiopharmacies in Brazil
249	Maria Emilia	TEJERÍA	Uruguay	Rational Development of A Family of Estradiol-Derived [^{99m} Tc]Tc Complexes Using in Silico Tools.
250	Samira	MARQUES DE CARVALHO	Brazil	Current Status of Radiopharmacies in Countries Member of The Ibero-American Forum of Radiological and Nuclear Regulatory Bodies: Licensing and Safety Requirements
254	Francesca	PORTO	Italy	Cyclotron-Production of Mn-52 for PET/MRI Imaging
255	Teresa	GHIRARDI	Italy	Advancement of Mn(II) Complexes for PET/MRI Imaging
256	Evangelia-Alexandra	SALVANOU	Greece	Iron Oxide Nanoparticles Radiolabeled with ⁶⁸ Ga & ¹⁷⁷ Lu for Breast Cancer Theranostics

Poster ID	Name		Organizations	Title of Paper
257	Georgios	LYMOURIS	Greece	The Synthesis and Pre-Therapeutic Introduction of N.C.A. ¹⁷⁷ Lu-PSMA I&T ("Lutescan") As A SPECT Compatible Radioligand for Imaging of Metastatic Prostate Cancer Patients, Candidates for ¹⁷⁷ Lu-PSMA Treatment
259	Kumissay	SERIKKANOVA	Kazakhstan	Use of The Radiopharmaceutical Sodium Iodide I131 in Kazakhstan.
263	Yin How	WONG	Malaysia	Development of a Novel Samarium-153 and Methotrexate loaded Particles for Chemical and Radiation Synovectomy of Rheumatoid Arthritis
265	Francesca	BARBARO	Italy	High-purity ⁵² Gm Mn Production: natV(α ,x) ⁵² Gm Mn and natCr(p,x) ⁵² Gm Mn at Comparison
267	Edgars	MAMIS	Latvia	Production by Mass-separation of Non-conventional Medical Radionuclides at the CERN-MEDICIS Facility
268	Marija	ATANASOVA LAZAREVA	North Macedonia	Development of an in-house Method for the Synthesis of Sodium [¹⁸ F]fluoride Preparation
269	Maja	CHOICHEVSKA	North Macedonia	Challenges in Method Developing of ¹⁸ F-FMISO Synthesis with Cartridge Purification
271	Tihomir Kirilov	BONEV	Bulgaria	"Radiopharmaceutical Drug Development while Using Adaptive Clinical Trial Design"
272	Julie Marie	CHAMPION	France	Innovative Medical Radioisotopes Production: A Focus on Pa Project
273	Arthur	BONGRAND	France	Latest Development of α Emitter Imaging and Quantification on a Large Field of View
274	Antoine	PINON	France	Automated Synthesis and Quality Control of [¹¹ C]metoclopramide Using iPhase C-11 Pro2 for Clinical PET Imaging
275	Arthur	BONGRAND	France	Recent Developments and Contribution to TAT of Systems Dedicated to Alpha Autoradiography
277	Adolfo	ZARATE-MORALES	Mexico	Initial Experience on the Cyclotron Production of Gallium-68 Using Solid Targets with 11 Mev Protons
279	Imma	CARBO BAGUE	Canada	In Vitro and in Vivo Evaluation of the Theranostic Radiopharmaceutical [¹⁹⁷ m/Ghg]Hg-Tcmc-Psma-617
280	Marina	BICALHO SILVEIRA	Brazil	Challenges of Adapting ¹⁸ F-Fluoroestradiol PET Imaging for Routine Clinical Applications in Brazil
282	Felipe	NUNES DAL BELO	Brazil	Application of Data Science and Artificial Intelligence in the Productive Efficiency of Radiopharmaceuticals
283	Wira Yusril	RAHMAN	Indonesia	The Effect of Particle Size [³² p]-Chromic Phosphate on the Stability of ³² p Radioisotopes in Silicone Patch
285	Efraín	ZAMORA ROMO	Mexico	Routine Production of [¹⁸ F]Alf-NOTA-Octreotide for PET Neuroendocrine Tumor Imaging At UNAM
286	Ali	BAHRAMI SAMANI	Iran, Islamic Republic of	Assessment of Mo-99 Radioisotope Supply Chain Using LEU in Iran
287	Simindokht	SHIRVANI ARANI	Iran, Islamic Republic of	Evaluation of the Produced ¹⁷⁷ Lu-Specific Activity Via Direct and Indirect Method Using Tehran Research Reactor
291	Asseel Hisham Ibrahim	ALREGIB	Malaysia	Physicochemical Characterisation and in-Vitro Cytotoxicity Test on A Novel Biodegradable Microsphere Loaded with Samarium-153 and Doxorubicin for Chemo-Radioembolization of Liver Cancer
292	Marko	KROSELJ	Slovenia	The Introduction of Novel Multipurpose Automated Module for Hospital Preparation of Theranostic Radiopharmaceuticals
293	Maryke	LUNDIE	South Africa	Optimisation of Selected Radiopharmacy Services in a Multidisciplinary Nuclear Medicine Setting in South Africa
294	Pinelopi Paraskevi	BOUZIOTI	Greece	Breast Tumor Specific ^{99m} Tc Carbonyl Conjugates of Trimeric (D and L) Alanine-Katti Peptides— Radiolabeling and Preclinical Investigations

Poster ID	Name		Organizations	Title of Paper
298	Yohannes Jorge	LAGEBO	Ethiopia	Establishment of the African Association of Radiopharmacy: Significant Steps Towards Improving Radiopharmacy Services in Africa
300	Juan	ESPOSITO	Italy	Status of the Cyclotron Driven LARAMED Project At INFN Legnaro National Laboratories
301	Emilija	JANEVIKJ-IVANOVSKA	North Macedonia	A European Network Dedicated to Targeted Alpha Therapy (TAT) With Astatine-211 – NOAR COST Action
308	Cristina Maria	MORIGUCHI JECKEL	Brazil	¹⁸ F-PSMA 1007 Production in A Cyclotron Facility: A Brazilian Experience
311	Marina	BICALHO SILVEIRA	Brazil	Strengthening Capabilities for Non-Clinical and Clinical Trials of New Radiopharmaceuticals for Medical Use in Brazil
312	Bianca	SCHACHERL	Germany	Toward Understanding ²²⁵ Ac ³⁺ Radionuclide Bonding Properties within Radiopharmaceuticals: The Study of La ³⁺ Homologues
313	Julian	REES	United States of America	Prevention and Treatment of Unintended Dose: From Safer Therapies to Accident Preparedness
315	Parmissa Kaur	Randhawa	Canada	Coordination, Radiolabeling and Kinetic Inertness of the Theranostic Radiometals Mercury-197m/G With P-SCN-Bn-TCMC-PSMA-617
316	Ruben	DALLAKYAN	Armenia	Medical radioisotope production technology development in Armenia
318	Jakub	BORATYNSKI	Poland	High Quality of Gallium-68 Chloride [⁶⁸ Ga]GaCl ₃ Production
319	Thomas	EBENHAN	South Africa	Advancing Nuclear Imaging of Infection: A South African Initiative Using Gallium-68-Functionalized Peptides – an Experience Report
321	Joao Alberto	OSSO JUNIOR	Brazil	The Use of Radioactive Tracers on Conventional Drug Development: A Critical View
351	Maria	COJOCARU-TOMA	Republic of Moldova	Prospects for the Use of New Types of Radiopharmaceutical Products
359	Kofi Adesi	KYEI	Ghana	Dosimetric Evaluation of Intensity Modulated Radiotherapy and Three-Dimensional Conformal Radiotherapy Treatment Planning of Prostate Cancer at an Oncology Center in Ghana

Thursday, 20 April 2023

14:00-15:30 Virtual E-poster II

Venue: Second Floor, M02 Exhibition Area E-Poster Stations

Poster ID	Name	Organizations	Title of Paper
153	Javier Gabriel	GIGLIO BAROSSO Uruguay	Comparison of Three Different Alternatives for Labelling PSMA under GMP Conditions
154	Javier Gabriel	GIGLIO BAROSSO Uruguay	Automated synthesis of [¹⁸ F] Favipiravir on a Synthra RNplus research platform
155	Rosanna	MORALES Peru	COVID-19 Lock-Downs as Management Opportunities in Radio-Pharmaceuticals Utilisation in Nuclear Medicine in Peru
183	Ivy Angelica	NUÑEZ Philippines	Establishment of the Nuclear Medicine Research and Innovation Center for the Development of Emerging PET Radiopharmaceuticals
184	Rizalina	OSORIO Philippines	"Recent Radiopharmaceutical Utilization Profiles in the Philippines"
201	Cristina	BOLZATI Italy	ws-[^{99m} Tc(N)(PNP3OH)] ₂ ⁺ : a Water Soluble Synthron for the Labelling of Protein Scaffolds
202	Ahmad	KURNIAWAN Indonesia	Targeting SOX9 Signaling Pathway for Colorectal Cancer Stem Cell Inhibition Using Bi-213 Labelled Evodiamine: An in-Silico Study
203	Nicola	SALVARESE Italy	Impact of Different [^{99m} Tc][Tc(N)PNP]-Scaffolds On The Labeling of The Rgd _{fk} Peptide and The Biological Properties of The Obtained Radiocompounds
205	Carolina	GOBBI Italy	[^{99m} Tc][Tc(CO) ₃]-Labeling of Scfv _{d2b} -Hystag for SPECT Imaging of PSMA in Prostate Cancer
206	Soumen	DAS India	Design, Synthesis and Preliminary Evaluation of A ⁶⁸ Ga-Labeled Thia Fatty Acid Derivative Towards Pet Imaging of Myocardial Metabolic Abnormalities
207	Chanda	ARJUN India	Applying The Reduce, Reuse, and Recycle Principle in The User-Friendly Sterility Testing Method for Injectable Radiopharmaceuticals
208	Chanda	ARJUN India	Bacterial Endotoxin Testing of Injectable Radiopharmaceuticals: Vendor Qualification
209	Vishwas	MURHEKAR India	Cationic Modification of C-18 Reverse Phase HPLC Column for Quality Control Analysis of ¹³¹ I-Sodium Iodide Solution
212	Md Nahid	HOSSAIN Bangladesh	Production of Radioisotopes at The Medical Cyclotron Facilities in Bangladesh: Experiences & Perspectives
213	Md Nahid	HOSSAIN Bangladesh	Optimization of F-18 Radioisotope Production With 18 Mev Cyclotron at The National Institute of Nuclear Medicine and Allied Sciences, Bangladesh
215	Badra	RATTYANANDA Indonesia	Development of Radiopharmaceutical for Lung Cancer Therapy Using Curcumin and Scandium Radiotracer
219	Noeen	MALIK United States of America	Radiopharmaceuticals Development – Bench to Clinic
220	Marita	JAKANOVA Kazakhstan	NROC: Opportunities and Perspectives of Radiopharmaceuticals
221	Zahra	HAGHGOO Iran, Islamic Republic of	A Preliminary Theranostic Candidate for NK1R Positive Tumors: Design, Synthesis, Labeling and Affinity Studies.
222	Ashok Ratanlalji	CHANDAK India	Comparative Evaluation of Renal Functions Using ⁶⁸ Ga-DOTATATE and Conventional Nuclear Imaging Modalities in Patients Being Planned for Peptide Receptor Radionuclide Therapy (PRRT)
223	Aaditya	SHAH India	An Automated Module for Easy and Facile Separation of No Carrier Added Lutetium-177 From Irradiated Enriched Ytterbium-176 Targets

Poster ID	Name	Organizations	Organizations	Title of Paper
233	Herlan	SETIAWAN	Indonesia	The large-scale production of Technetium-99m (Tc-99m) From Natural Molybdenum is a Challenge For Diagnostic Radionuclides
235	Abdulmajeed	IBRAHIM	Nigeria	The need for Radio Isotopes Production in Sub Sahara Africa for Qualitative Health Care Delivery and Cancer Treatment for Sustainable Development: Case Study Nigeria
242	Ratna Dini	HARYUNI	Indonesia	Nimotuzumab Fragment-based Radiopharmaceutical for Targeting EGFR-overexpressing Tumor Cells
245	Beatriz	SALINAS	Spain	Immunopet Imaging of Staphylococcal Infections in Osteomyelitis Mouse Model
258	Jelena	PETROVIC	Serbia	Radioloabelling of Ciprofloxacin in the Detection of Abdominal and Gastrointestinal Infection
276	Florencia	MENENDEZ MIGUES	Uruguay	Computational Approach to the Evaluation of Stability in Radiotracers
281	Gurvinder	KAUR	India	Translational Study to Determine the Diagnostic Efficacy of ⁶⁸ Ga-duramycin for Anthracycline Induced Cardiotoxicity
290	Manish	DIXIT	India	Production of Zr-89 via Pressed Y-89 Powder Solid Target and its Application to Biomolecule Labelling
296	Marianna	TOSATO	Italy	Capturing the Theranostic Meitner-Auger Emitter Mercury-197m/g with Sulfur-Rich Macrocyclic Platforms
299	Dulanjalee	RAJAPAKSHA KANKANAMGE	Sri Lanka	Enhancing the Life Expectancy of Cancer Patients by Setting up the First Radiopharmaceutical Production Facility in Sri Lanka
304	María Isabel	GONZÁLEZ	Spain	Novel ¹⁷⁷ -Lu Exosome-based Nanoprobes for Theranostic in Cancer
309	Fabio Luiz	NAVARRO MARQUES	Brazil	A Multimodality Training Program Focusing on the Qualification of Professionals for Radiopharmacy: The Medicine School of the University of São Paulo Case
324	Fabio Luiz	NAVARRO MARQUES	Brazil	Direct Radiolabeling of PVP-Nanogel From ^{99m} TcO ₄ -Reaction

FORTHCOMING SCIENTIFIC CONFERENCES SCHEDULED BY THE IAEA

2023

International Symposium on Uranium Raw Material for the Nuclear Fuel Cycle: Innovation for Sustaining Future Resources and Production (URAM-2023) (CN-311)

8-12 May, Vienna, Austria

International Conference on Nuclear Decommissioning: Addressing the Past and Ensuring the Future (CN-312)

15-19 May, Vienna, Austria

International Conference on Computer Security in the Nuclear World: Security for Safety (CN-313)

19-23 June, Vienna, Austria

International Symposium on Isotope Hydrology: Enhancing Water Security in a Changing World (CN-320)

3-7 July, Vienna, Austria

Second International Conference on Climate Change and the Role of Nuclear Power (CN-315)

9-13 October, Vienna, Austria

29th IAEA Fusion Energy Conference (CN-316)

16-21 October, London, United Kingdom

International Conference on the Safety of Radioactive Waste Management, Decommissioning, Environmental Protection and Remediation: Ensuring Safety and Enabling Sustainability (CN-318)

6-10 November, Vienna, Austria

International Conference on Research Reactors: Achievements, Experience and the Way to a Sustainable Future (CN-319)

27-30 November, Dead Sea, Jordan

for information on forthcoming scientific meetings, please consult the IAEA web site:

<https://www.iaea.org/events>

PARTICIPATION IN IAEA SCIENTIFIC CONFERENCES

Governments of Member States and those organizations whose activities are relevant to the conference subject matter are invited to designate participants. In addition, the IAEA itself may invite a limited number of scientists as invited speakers. Only participants designated or invited in this way are entitled to present papers and take part in the discussions.

Scientists interested in participating in any of the IAEA conferences should request information from the Government authorities of their own countries, in most cases the Ministry of Foreign Affairs or national atomic energy authority.

PUBLICATIONS

Proceedings

The proceedings of the conference containing all presentations and posters delivered at the conference, as well as the findings and recommendations, will be published by the IAEA as soon as possible after the conference.

ORDERS

No registration fee is charged to participants but they are encouraged to order for themselves or on behalf of their supporting organization at least one copy of the proceedings. These can be obtained at a special price representing half the estimated sales price provided that they are ordered and paid for during the conference at the Conference Desk.

Other IAEA Publications

All IAEA publications may be ordered directly from the Sales and Promotion Unit, International Atomic Energy Agency, P.O. Box 100, A-1400 Vienna, Austria. Fax: (+43 1) 2600-29302 Email: sales.publications@iaea.org Internet: <http://www.iaea.org/book>

IAEA PUBLICATIONS RELATED TO THE SUBJECT OF THE EVENT

IAEA Radioisotopes and Radiopharmaceuticals Series No. 8

[Guidance for Preclinical Studies with Radiopharmaceuticals | IAEA](#)

STI/PUB/1961, IAEA Radioisotopes and Radiopharmaceuticals Series No.7, Publ 2022

[Copper-64 Radiopharmaceuticals: Production, Quality Control and Clinical Applications | IAEA](#)

STI/PUB/1674, IAEA Radioisotopes and Radiopharmaceuticals Series No.6, Publ 2015

[Radiopharmaceuticals for Sentinel Lymph Node Detection: Status and Trends | IAEA](#)

STI/PUB/1662, IAEA Radioisotopes and Radiopharmaceuticals Series No.5, Publ 2015

[Yttrium-90 and Rhenium-188 Radiopharmaceuticals for Radionuclide Therapy | IAEA](#)

STI/PUB/1563, IAEA Radioisotopes and Radiopharmaceuticals Series No.4, Publ 2012

[Cyclotron Produced Radionuclides: Operation and Maintenance of Gas and Liquid Targets | IAEA](#)

STI/PUB/1515, IAEA Radioisotopes and Radiopharmaceuticals Series No.3, Publ 2012

[Cyclotron Produced Radionuclides: Guidance on Facility Design and Production of Fluorodeoxyglucose \(FDG\) | IAEA](#)

STI/PUB/1436, IAEA Radioisotopes and Radiopharmaceuticals Series No.2, Publ 2010

[Production of Long Lived Parent Radionuclides for Generators: 68Ge, 82Sr, 90Sr and 188W | IAEA](#)

STI/PUB/1405, IAEA Radioisotopes and Radiopharmaceuticals Series No.1, Publ 2010

[Technetium-99m Radiopharmaceuticals: Status and Trends | IAEA](#)

STI/PUB/1937, IAEA Radioisotopes and Radiopharmaceuticals Reports 4, Publ 2021

[Alternative Radionuclide Production with a Cyclotron | IAEA](#)

STI/PUB/1915, IAEA Radioisotopes and Radiopharmaceuticals Reports 3, Publ 2021

[Production, Quality Control and Clinical Applications of Radiosynovectomy Agents | IAEA](#)

STI/PUB/1743, IAEA Radioisotopes and Radiopharmaceuticals Reports 2, Publ 2017

[Cyclotron Based Production of Technetium-99m | IAEA](#)

STI/PUB/1717, IAEA Radioisotopes and Radiopharmaceuticals Reports 1, Publ 2016

[Cyclotron Produced Radionuclides: Emerging Positron Emitters for Medical Applications: ⁶⁴Cu and ¹²⁴I | IAEA](#)

IAEA TECDOC Series No. 1968

[Production and Quality Control of Fluorine-18 Labelled Radiopharmaceuticals | IAEA](#)

IAEA-TECDOC-1955, IAEA TECDOC Series No. 1955, Publ 2021

[Production of Emerging Radionuclides towards Theranostic Applications: Copper-61, Scandium-43 and -44, and Yttrium-86 | IAEA](#)

IAEA-TECDOC-1945, IAEA TECDOC Series No. 1945, Publ 2021

[Therapeutic Radiopharmaceuticals Labelled with Copper-67, Rhenium-186 and Scandium-47 | IAEA](#)

IAEA-TECDOC-1883, IAEA TECDOC Series No. 1883, Publ 2019

[Training Curriculum for Nuclear Medicine Physicians | IAEA](#)

IAEA-TECDOC-1856, IAEA TECDOC Series No. 1856, Publ 2018

[Quality Control in the Production of Radiopharmaceuticals | IAEA](#)

IAEA TECDOC Series No. 1863

[Gallium-68 Cyclotron Production | IAEA](#)

IAEA-TECDOC-1715, IAEA TECDOC Series No. 1715, Publ 2013

[Commercial Products and Services of Research Reactors | IAEA](#)

STI/PUB/1965, IAEA Human Health Reports No. 19, Publ 2022

[A Model to Assess Staffing Needs in Nuclear Medicine | IAEA](#)

STI/PUB/1605, IAEA Human Health Reports No. 9, Publ 2014

[Quantitative Nuclear Medicine Imaging: Concepts, Requirements and Methods | IAEA](#)

IAEA Human Health Series No. 45

[PET-CT for the Management of Cancer Patients: a Review of the Existing Evidence | IAEA](#)

IAEA Human Health Series No. 38

[Atlas of Non-FDG PET-CT in Diagnostic Oncology | IAEA](#)

IAEA Human Health Series No. 37

[Nuclear Medicine Resources Manual 2020 Edition | IAEA](#)

IAEA Safety Standards Series SSG-59

[Radiation Safety of Accelerator Based Radioisotope Production Facilities | IAEA](#)

STI/DOC/010/480 (Rev.1) Technical Reports Series No. 480 (Rev.1), Publ 2022

[Research Reactor Benchmarking Database: Facility Specification and Experimental Data \(Revision\) | IAEA](#)

STI/DOC/010/478 Technical Reports Series No. 478, Publ 2015

[Feasibility of Producing Molybdenum-99 on a Small Scale Using Fission of Low Enriched Uranium or Neutron Activation of Natural Molybdenum | IAEA](#)

STI/PUB/1627 IAEA Nuclear Energy Series No. NP-T-5.3, Publ 2014

[Applications of Research Reactors | IAEA](#)

STI/PUB/1913 Proceedings Series, Publ 2020

[Trends in Radiopharmaceuticals \(ISTR-2019\) | IAEA](#)